Global Klebsiella Infection Market – Industry Trends and Forecast to 2029

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Global Klebsiella Infection Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Sep 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Klebsiella Infection Market, By Treatment (Moxifloxacin, Ofloxacin, Levofloxacin, Ceftriaxone), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029

Klebsiella Infection Market

Klebsiella Infection Market Analysis and Size

The global Klebsiella infection market is expected to witness significant growth during the forecast period.  Rising prevalence of Klebsiella infections worldwide and emerging markets are the factors responsible for the growth of this market. The market is on the rise due to increase in the treatment procedures, R&D activities funded by government and rise in the population in this region. Klebsiellae account for almost 8% of all hospital-acquired infections. COVID-19 also had a major impact on the market growth.

 Data Bridge Market Research analyses a growth rate in the global Klebsiella infection market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Klebsiella infections are mostly hospital acquired and patients who have weak immune system are more prone to these infections. Patients with a weak immune system or the ones who have an implanted medical device are at higher risk for Klebsiella infections. Wide use of antibiotics has resulted in the development of antibiotic-resistant strains of Klebsiella.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Treatment (Moxifloxacin, Ofloxacin, Levofloxacin, Ceftriaxone), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Procarta Biosystems (U.K.), La Jolla Pharmaceutical Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Merck KGaA (Germany), Beckman Coulter Inc. (U.S.), bioMerieux (France), Bio-Rad Laboratories, Inc (U.S.), Quidel Corporation (U.S.), Eiken Chemical Co., Ltd. (Japan), Melinta Therapeutics LLC (U.S.), Northern Antibiotics Ltd (Finland), Sumitomo Pharma Co., Ltd. (Japan)

Market Opportunities

  • Availability of Advanced Treatment Procedures
  • Increasing Demand for Retail Pharmacies

Global Klebsiella Infection Market Dynamics

Drivers

  • Increased Demands of Diagnostic Tests

Different kinds of diagnostic procedures are helping to create opportunities of the global Klebsiella infection market. Tests such as laboratory tests, ultrasound, X-rays and many such other tests are available today with regards to this. All these factors are also contributing in the growth of the market

  • Increase in the number of research and development activities       

The market's growth is fueled by increase in the number of R&D activities. This will provide beneficial advantages for the global Klebsiella infection market. To encourage researchers and pharmaceutical companies to develop novel medicines, the government is funding research and development (R&D) initiatives. For instance, Tetraphase Pharmaceuticals, Inc. was funded with USD 67 million for the development of its pipeline drug TP-434. This is a potent antibiotic effective against multi drug resistant (MDR) gram negative microorganism and can aid in providing effective treatment in Klebsiella infection.

Opportunities

  • Availability of Advanced Treatment Procedures

With each passing decade, varied treatment methods are being available that would help the patients' faster recovery. Treatment advancements in terms of new antibiotics are on the rise. Thus, it creates many opportunities in the market growth.

  • Increasing Demand for Retail Pharmacies

The rise in the number of perinatal infections therapeutics being delivered through the retail pharmacies and the rising number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global Klebsiella infection market over a forecast period.

  • High Cost

The huge expenditure associated with Klebsiella infections medications surely hamper the market growth.

This global Klebsiella infection market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global Klebsiella infection market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Klebsiella infection Market Scope

The global Klebsiella infection market is segmented on the basis of treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

  • Moxifloxacin
  • Ofloxacin
  • Levofloxacin
  • Ceftriaxone

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Klebsiella Infection Market Regional Analysis/Insights

The global Klebsiella infection market is analysed and market size insights and trends are provided by treatmnet, distribution channel and end-user as referenced above.

The major countries covered in the global Klebsiella infection market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global Klebsiella infection market throughout the forecasted period due to rising prevalence of the infection

Asia-Pacific dominates the market due to increased WHO & government awareness programs.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Klebsiella Infection Market Share Analysis

The global Klebsiella infection market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global Klebsiella infection market

Key players operating in the global Klebsiella infection market include:

  • Procarta Biosystems (U.K.)
  • La Jolla Pharmaceutical Company (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Pfizer Inc. (U.S.), Novartis AG (Switzerland)
  • AstraZeneca (U.K.)
  • Johnson & Johnson Private Limited (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Bristol-Myers Squibb Company (U.S.)
  • Lilly (U.S.)
  • Amgen Inc. (U.S.)
  • Merck KGaA (Germany)
  • Beckman Coulter Inc. (U.S.)
  • bioMerieux (France)
  • Bio-Rad Laboratories, Inc (U.S.)
  • Quidel Corporation (U.S.)
  • Eiken Chemical Co., Ltd. (Japan)
  • Melinta Therapeutics LLC (U.S.)
  • Northern Antibiotics Ltd (Finland)
  • Sumitomo Pharma Co., Ltd. (Japan)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

Availability of advanced treatment procedures & increasing demand for retail pharmacies are the Klebsiella infection market opportunities.
Asia-Pacific dominates the Klebsiella infection market due to increased WHO & government awareness programs.
Increased demands of diagnostic tests & increase in the number of research and development activities are the growth drivers of the Klebsiella infection market.
Treatment, distribution channel and end-user are the factors on which the Klebsiella infection market research is based.
Major companies in the Klebsiella infection market are Procarta Biosystems (U.K.), La Jolla Pharmaceutical Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Sun Pharmaceutical Industries Ltd. (India), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), Amgen Inc. (U.S.), Merck KGaA (Germany), Beckman Coulter Inc. (U.S.), bioMerieux (France), Bio-Rad Laboratories, Inc (U.S.), Quidel Corporation (U.S.), Eiken Chemical Co., Ltd. (Japan), Melinta Therapeutics LLC (U.S.), Northern Antibiotics Ltd (Finland), Sumitomo Pharma Co., Ltd. (Japan).